ACC 2026 Statements: Prevention of Thrombotic Events/Antiplatelet Therapy in the Management of ASCVD

The 2026 Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events Scientific Statement and the 2026 Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease Scientific StatementDirect Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events/Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular DiseaseAmerican College of CardiologyJune 30, 2026Guideline Summary: https://www.guidelinecentral.com/guideline/5230408/ / https://www.guidelinecentral.com/guideline/5230407/ Full-Text:  https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033 / https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2